U.S., Feb. 21 -- ClinicalTrials.gov registry received information related to the study (NCT07423494) titled 'Personalized Antisense Oligonucleotide Therapy for A Single Patient With CHCHD10 ALS (nL18576)' on Feb. 13.
Brief Summary: This research project entails delivery of a personalized antisense oligonucleotide (ASO) drug designed for a single participant with amyotrophic lateral sclerosis (ALS) due to a pathogenic variant in CHCHD10
Study Start Date: March, 2026
Study Type: INTERVENTIONAL
Condition:
Amyotrophic Lateral Sclerosis
Intervention:
DRUG: nL-CHCHD-001
Personalized antisense oligonucleotide
Recruitment Status: NOT_YET_RECRUITING
Sponsor: n-Lorem Foundation
Disclaimer: Curated by HT Syndication....